Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team. What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has joined Cambridge, Massachusetts-based Moderna as director of hematology, according to a Twitter post by the researcher.

Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know

Moderna stock has declined by about 25% over the last month and by close to 17% over the last two trading days alone. So what's driving the sell-off?

Why Moderna Stock Is Down 25% Over The Last Month

Magna International

ArcelorMittal

Winnebago

Level up your portfolio with high earnings yield stocks including ArcelorMittal (MT), Moderna, (MRNA), Shell (RDS.A), Magna (MGA), Winnebago (WGO).

5 High Earnings Yield Picks That Command Your Attention

Takeda Pharmaceutical

Shares of Moderna Inc. were down 0.9% in premarket trading on Friday after the company said it is pursuing approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. . Takeda submitted the new drug application and will be tasked with importing and distributing the vaccine from the Cambridge, Mass.

Moderna, via Takeda, seeks authorization for COVID-19 vaccine in Japan

Johnson & Johnson

Pfizer

Testing vaccines against new variants will be much easier than it might otherwise have been.

Why the FDA's Coronavirus Variant Guidance Is Great News for Pfizer, Moderna, and Johnson & Johnson

Why New COVID Strains May Mean More Revenue for Pfizer and Moderna

Both companies are on their way to vaccinating most Americans.

Vaccine Rollout: Where Does Moderna Stand Versus Pfizer?

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has asked regulators to approve the use of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (mRNA-1273 or TAK-919). Takeda filed the New Drug Application to import and distribute the shot.

Takeda Seeks Approval For Moderna's COVID-19 Shot In Japan

Moderna Inc. (NASDAQ: MRNA) and International Business Machines Corp. (NYSE: IBM) plan to collaborate on technologies that could help support smarter management of COVID-19 vaccines, including improving supply chain management and real-time tracking of vaccines. What Happened: The companies said Thursday they will focus on technologies such as artificial intelligence, blockchain and hybrid cloud to help improve information sharing among governments and health care providers to address potential supply chain disruptions.

Moderna To Collaborate With IBM On COVID-19 Vaccine Distribution — Utilizing Blockchain Tech

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces New Drug Application submitted to import and distribute Moderna's COVID-19 vaccine candidate in Japan.

Moderna Announces New Drug Application Submitted to Import and Distribute Moderna's COVID-19 Vaccine Candidate in Japan

Vaccine maker Moderna Inc and IBM Corp said on Thursday they would work together on technologies to track COVID-19 vaccine administration.

Moderna, IBM team up on COVID-19 vaccine distribution data

Moderna Inc. and International Business Machines Corp. announced Thursday plans to work together to find technologies to support "smarter COVID-19 vaccine management." The technologies the companies will explore include artificial intelligence, blockchain and hybrid cloud, the companies said.

Moderna, IBM explore blockchain tech, AI to support 'smarter' management of COVID-19 vaccines

CAMBRIDGE, Mass. and ARMONK, N.Y., March 4, 2021 /PRNewswire/ -- Today, Moderna (Nasdaq: MRNA) and IBM (NYSE: IBM) announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine...

Moderna and IBM Plan to Collaborate on COVID-19 Vaccine Supply Chain and Distribution Data Sharing

BioNTech SE

Should You Be Concerned About mRNA COVID Vaccines?

It's more achievable than you might think.

Why Moderna Could Be Worth $100 Billion Within 5 Years

Investors appear to be jittery about good news for rival COVID-19 vaccines.

Why Moderna Stock Is Sinking Again Today

AstraZeneca

Pharma giant AstraZeneca sold its stake in Moderna for more than $1 billion last year as the upstart biotech firm's COVID-19 vaccine thrust it into the spotlight. AstraZeneca quietly revealed the move in its February annual report, which said the Moderna sale accounted for “a large proportion” of the roughly $1.4 billion it raked in.

AstraZeneca cashed out Moderna stake for $1 billion in 2020

AstraZeneca Just Sold Its Moderna Stock: Should You?

Moderna's CEO Calls These 3 Elements "Critical" for Vaccine Success

The biotech's recent earnings report offered a few clues.

Here's How Moderna Is Ensuring Its Lead in the Coronavirus Vaccine Market

Fauci's statement comes amid rising calls to prioritize the first dose to ensure more people are vaccinated faster.

Dr. Fauci Insists U.S. Will Stick To Two Dose Strategy For Pfizer, Moderna Vaccines

A Leader in Covid-19 Vaccine and a Company Showing Positivity.

Top Stock Picks for Week of March 1, 2021

The cash from the sale of its Moderna holding will help shore up AstraZeneca's finances as it continues to develop its drug pipeline.

AstraZeneca Sold Its Stake in Rival Vaccine Maker Moderna for Over $1 Billion

Moderna Delivers The Bad News

AstraZeneca plc (LON:AZN) has reportedly cashed in US$1.2bn after selling its 7.7% stake in COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA). The FTSE 100 pharma giant will use the proceeds to shore up its balance sheet as it is about to complete the US$39bn acquisition of US rare diseases specialist Alexion, its biggest yet, The Times reported.

News for Moderna Stock (MRNA)